Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
about
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyOncolytic adenovirus-mediated therapy for prostate cancerOncolytic virotherapy of canine and feline cancerTrial Watch-Oncolytic viruses and cancer therapyEvolution of animal models in cancer vaccine developmentAdenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-regionCell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model.Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Advances in preclinical investigation of prostate cancer gene therapy.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusComplete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirusIn situ immunization via non-surgical ablation to prevent local and distant tumor recurrence.Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Increasing the efficacy of oncolytic adenovirus vectorsINGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.A fully replication-competent adenovirus vector with enhanced oncolytic propertiesYeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosineOn the potential of oncolytic virotherapy for the treatment of canine cancers.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Armed replicating adenoviruses for cancer virotherapy.Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsEfficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.Oncolytic virus therapy for prostate cancer.Viral-based gene delivery and regulated gene expression for targeted cancer therapy.Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice.Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy.Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.Directed adenovirus evolution using engineered mutator viral polymerases.Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
P2860
Q27001601-D33B65F9-0C89-4442-AADF-F6B4B15A9B59Q27004796-8CBDBD48-B94F-4399-B7EA-3585ED8BF572Q27008306-886CC84A-B5B6-41F0-970F-E00262CADFAEQ28072347-6EA25B62-933D-494A-A6C1-100C71D39443Q28080739-076489A7-C65E-4BE0-9D11-8FA14C9763E1Q28484203-931F2845-2121-4678-862E-AEC320EE82DAQ30525107-EC54B94F-FD75-42D8-8019-2DED6E232443Q33622711-6002199A-B831-4637-85C9-AEAD253F1005Q33677054-49360717-51A9-45BD-B7DC-2865F7F18F1BQ33690982-68432FBB-46F8-42A6-B089-06A295FB2561Q34124614-2E9EE079-61AF-457B-B786-D8896D9207A2Q34475389-70869ADC-2F3A-4712-AA81-5DD0885B9B48Q35201826-C556EFAD-BD48-4E5F-890F-E6DED9716CDBQ35261325-CEF25FFF-81C4-4760-9CB4-9B180265A199Q36209205-818B771B-C090-440A-95AB-968CB89FE099Q36221367-D5BF6C92-7BF1-4B43-9ED2-F054EED91B4BQ36580716-3F2D077F-E5F0-4862-AA35-7E782F6E1D1EQ37031925-DC053414-0B38-48A0-BF23-59A4CCC1A063Q37191007-081CE21F-DEBD-44A3-A5BE-508AEDD65005Q37386616-CDF370C8-6252-472D-BEEA-0C191FA12BF8Q37442235-CC022C4F-09D5-4B64-A63F-AF881CCF0455Q37448016-50A6C5E3-62A5-40BE-811C-B5D08D745B80Q37615535-4C2389C2-8F5E-439F-BED1-3644E918EBB1Q37641366-22346EA8-6C90-4CC2-9B9C-3B51CFA09D1CQ38466750-E5EC8D98-B1C4-481F-92CA-96F006E92F51Q39178068-C07A1AD8-2188-4E84-955A-101C82FD430BQ39331992-B534C99B-2B11-4A99-965F-C8C932B8EACAQ39622784-89815CB5-768A-4481-8A6F-F5597FA1059EQ40026347-8F5DAF31-2EB8-433E-B585-DEDC8E8F297AQ40585840-A3E57530-AEC3-4AD7-9BB0-5DA3C79B1A1FQ47549552-58A1426C-4225-47F9-8CB8-8C3D2D1A8CC1Q59117175-346D2B22-AC26-447B-AD5E-CD7FD2910DF1
P2860
Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Second-generation replication- ...... cy without increased toxicity.
@en
type
label
Second-generation replication- ...... cy without increased toxicity.
@en
prefLabel
Second-generation replication- ...... cy without increased toxicity.
@en
P2093
P921
P1433
P1476
Second-generation replication- ...... cy without increased toxicity.
@en
P2093
Dell Paielli
Jae Ho Kim
John Seely
Kenneth N Barton
Stephen L Brown
Svend O Freytag
Sweaty Koul
Yingshu Zhang
P304
P356
10.1016/J.YMTHE.2005.10.005
P577
2005-11-14T00:00:00Z